WEKO3
アイテム
{"_buckets": {"deposit": "a8a5c70f-90f1-404f-b1a9-98fa220fc100"}, "_deposit": {"id": "23914", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "23914"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00023914", "sets": ["501"]}, "author_link": ["70998", "70999", "71000", "71001", "71002", "71003"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageEnd": "1404", "bibliographicPageStart": "1393", "bibliographicVolumeNumber": "8", "bibliographic_titles": [{"bibliographic_title": "Immunotherapy", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "http://doi.org/10.2217/imt-2016-0076"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/26117"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Future Medicine", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.2217/imt-2016-0076", "subitem_relation_type_select": "DOI"}}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1750-743X", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kuramitsu, Shunichiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamichi, Akane", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohka, Fumiharu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motomura, Kazuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71001", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hara, Masahito", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71002", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Natsume, Atsushi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71003", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-12-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "0815Review_Figures.pdf", "filesize": [{"value": "334.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 334700.0, "url": {"label": "0815Review_Figures.pdf ファイル公開:2017/12/01", "objectType": "dataset", "url": "https://nagoya.repo.nii.ac.jp/record/23914/files/0815Review_Figures.pdf"}, "version_id": "22838a25-7eec-4984-8ae0-2dbc6488fcdb"}, {"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-12-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 1, "filename": "20160815revision_kuramitsu_ACT_review_v11.pdf", "filesize": [{"value": "249.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 249600.0, "url": {"label": "20160815revision_kuramitsu_ACT_review_v11.pdf ファイル公開:2017/12/01", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/23914/files/20160815revision_kuramitsu_ACT_review_v11.pdf"}, "version_id": "c419b299-6256-494e-bfa9-070a7fa7583c"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/26117", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2017-04-21"}, "publish_date": "2017-04-21", "publish_status": "0", "recid": "23914", "relation": {}, "relation_version_is_last": true, "title": ["Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities"], "weko_shared_id": -1}
Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities
http://hdl.handle.net/2237/26117
http://hdl.handle.net/2237/26117e0f80cc0-e8e6-4c3c-ba66-c8b0459a6e3c
名前 / ファイル | ライセンス | アクション |
---|---|---|
0815Review_Figures.pdf ファイル公開:2017/12/01 (334.7 kB)
|
|
|
20160815revision_kuramitsu_ACT_review_v11.pdf ファイル公開:2017/12/01 (249.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-04-21 | |||||
タイトル | ||||||
タイトル | Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities | |||||
言語 | en | |||||
著者 |
Kuramitsu, Shunichiro
× Kuramitsu, Shunichiro× Yamamichi, Akane× Ohka, Fumiharu× Motomura, Kazuya× Hara, Masahito× Natsume, Atsushi |
|||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
抄録 | ||||||
内容記述 | Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed. | |||||
言語 | en | |||||
内容記述タイプ | Abstract | |||||
出版者 | ||||||
言語 | en | |||||
出版者 | Future Medicine | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプresource | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.2217/imt-2016-0076 | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 1750-743X | |||||
書誌情報 |
en : Immunotherapy 巻 8, 号 12, p. 1393-1404, 発行日 2016-12 |
|||||
著者版フラグ | ||||||
値 | author | |||||
URI | ||||||
識別子 | http://doi.org/10.2217/imt-2016-0076 | |||||
識別子タイプ | DOI | |||||
URI | ||||||
識別子 | http://hdl.handle.net/2237/26117 | |||||
識別子タイプ | HDL |